Global H1N1 Vaccines Market to Grow at a CAGR of 4.17% During 2016-2020
The high level of maturity in the H1N1 vaccines market has renewed the push to develop quadrivalent vaccines that address areas of the market with unmet medical needs. Vaccines that prevent H1N1 have been a long-standing void in the treatment algorithm. Therefore, the introduction advanced vaccines in the next decade will likely alter the global H1N1 vaccines market landscape. Sanofi, AstraZeneca, and VaxInnate have also invested in quadrivalent vaccines, such as Sanofi's VaxiGrip, VaxInnate's VAX2012Q, and AstraZeneca's MEDI-550 vaccine, which...
View full press release